|

VX15/2503 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-SEMA4D Monoclonal Antibody VX15/2503, Pepinemab, moAb VX15/2503

Pipeline

Phase 1: 1

Top Sponsors

  • Emory University1

Indications

  • Squamous Cell Carcinoma of the Head and Neck1
  • Cancer1

Atlanta, Georgia1 trial

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Emory University Hospital Midtown

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.